Development of hepatitis C virus production reporter-assay systems using two different hepatoma cell lines by Takeda, Midori et al.
 1 
Development of Hepatitis C Virus Production Reporter Assay Systems Using Two 1 
Different Hepatoma Cell Lines  2 
 3 
Midori Takeda,1 Masanori Ikeda,1* Yasuo Ariumi,1, 3 Takaji Wakita,2 and Nobuyuki 4 
Kato1 5 
 6 
1Department of Tumor Virology, Okayama University, Graduate School of Medicine, 7 
Dentistry, and Pharmaceutical Sciences, Okayama, Japan 8 
2Department of Virology II, National Institute of Infectious Disease, Tokyo, Japan 9 
 10 
Key words: HCV; adaptive mutation; NS5B; renilla luciferase; HuH-7; Li23 11 
 12 
*Corresponding author. Mailing address: Department of Tumor Virology, Okayama 13 
University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 14 
Okayama 700-8558, Japan 15 
Phone: +81-86-235-7386. 16 
 2 
FAX: +81-86-235-7392. 17 
e-mail: maikeda@md.okayama-u.ac.jp 18 
 19 
3Current address: Center For AIDS Research, Kumamoto University, Kumamoto 20 
860-0811, Japan. 21 
 22 
Running title: HCV production reporter assay systems 23 
 24 
 25 
 26 
Abstract: 250 words  27 
Text: 5062 words (w/o Refs.)  28 
Figures and Tables: Tables, 0; Figures, 6  29 
Supplementary Figures: 3 30 
 31 
 32 
 3 
 33 
Summary 34 
 35 
The hepatitis C virus (HCV) infection system was developed using the HCV JFH-1 36 
strain (genotype 2a) and HuH-7 cells, and this cell culture is so far the only robust 37 
production system for HCV. In patients with chronic hepatitis C, the virological effects 38 
of pegylated interferon and ribavirin therapy differ depending on the HCV strains and 39 
genetic background of the host. Recently, we reported the hepatoma-derived Li23 cell 40 
line, in which the JFH-1 life cycle was reproduced at a level almost equal to that in the 41 
HuH-7-derived cell line. To monitor the HCV life cycle more easily, we here developed 42 
JFH-1 reporter assay systems using both the HuH-7- and Li23-derived cell lines.  43 
To identify the genetic mutations by long-term cell culture, HCV RNAs in HuH-7 at 44 
130 days after infection were amplified and subjected to sequence analysis to find the 45 
adaptive mutation for robust viral replication. We identified two mutations, H2505Q 46 
and V2995L, in the NS5B region. V2995L but not H2505Q enhanced JFH-1 RNA 47 
replication. However, we found that H2505Q but not V2995L enhanced HCV RNA 48 
 4 
replication of the strain O (genotype 1b). We also selected highly permissive D7 cells 49 
by serial subcloning of Li23 cells. The expression level of claudin-1 and Niemann-Pick 50 
C1-like 1 in D7 cells is higher than that in parental Li23 cells. 51 
In this study, we developed HCV JFH-1 reporter assay systems using two distinct 52 
hepatoma cell lines, HuH-7 and Li23. The mutations in NS5B resulted in different 53 
effects on strains O and JFH-1 HCV RNA replication. 54 
 55 
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Introduction 66 
 67 
   Hepatitis C virus (HCV) infection frequently causes chronic hepatitis and leads to 68 
liver cirrhosis and hepatocellular carcinoma. The elimination of HCV by antiviral 69 
reagents seems to be the most efficient therapy to prevent the fatal state of the disease. 70 
HCV belongs to the Flaviviridae family and contains a positive single-stranded RNA 71 
genome of 9.6 kb. The HCV genome encodes a single polyprotein precursor of 72 
approximately 3000 amino acid residues, which is cleaved by host and viral protease 73 
into at least 10 proteins in the following order: Core, envelope 1 (E1), E2, p7, 74 
non-structural 2 (NS2), NS3, NS4A, NS4B, NS5A, and NS5B (Kato, 2001; Kato et 75 
al., 1990; Tanaka et al., 1996).  76 
   The evaluation of anti-HCV reagents was difficult before the development of the 77 
HCV replicon system by Lohmann et al. in 1999 (Lohmann et al., 1999). The HCV 78 
replicon system enabled investigation of the anti-HCV reagents and the cellular factors 79 
involved in HCV RNA replication. Following the introduction of the replicon system, 80 
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the genome-length HCV RNA replication systems and reporter assay systems were also 81 
developed (Ikeda et al., 2005; Ikeda et al., 2002; Lohmann et al., 2001; 82 
Pietschmann et al., 2002). In 2005, an HCV infection system was developed using 83 
the genotype 2a JFH-1 strain (Lindenbach et al., 2005; Wakita et al., 2005; 84 
Zhong et al., 2005). The JFH-1 infection system has been used to study not only the 85 
viral RNA replication, but also viral infection and release. This HCV cell culture system 86 
was developed using the human hepatoma cell line HuH-7 and thus far HuH-7 is the 87 
only cell line to exhibit robust HCV production. Therefore, we intended to test the 88 
susceptibility of various other cell lines to HCV RNA replication. Recently we 89 
reported that the hepatoma cell line Li23 supported robust HCV RNA replication (Kato 90 
et al., 2009). Li23 was also susceptible to authentic JFH-1 infection (Kato et al., 91 
2009). Microarray analysis revealed that HuH-7 and Li23 cells exhibited distinct gene 92 
expression profiles (Mori et al., 2010). For example, we identified 3 genes (New York 93 
esophageal squamous cell carcinoma 1, !-defensin-1, and galectin-3) showing 94 
Li23-specific expression. Using HuH-7 and Li23 cells in combination with HCV strain 95 
O (genotype 1b), we developed drug assay systems, OR6 and ORL8, respectively, by 96 
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introducing the renilla luciferase (RL) gene (Ikeda et al., 2005; Kato et al., 2009). 97 
We found and reported that the sensitivities to anti-HCV reagents were different 98 
between the HuH-7 and Li23 assay systems. For example, the Li23 assay system was 10 99 
times more sensitive to ribavirin than the HuH-7 assay system (Mori et al., 2011). 100 
Methotrexate showed very strong anti-HCV activity in the Li23 assay system, although 101 
it showed very weak anti-HCV activity in the HuH-7 assay system (Ueda et al., 2011). 102 
These results encouraged us to develop a JFH-1 reporter assay system using HuH-7 and 103 
Li23 cells. This JFH-1 reporter assay system not only facilitated the monitoring of the 104 
viral infection and release, but also provided us with new information that could be 105 
missed in these steps when using only a HuH-7 assay system. However, the extension 106 
of the size of the viral genome by introducing exogenous genes (RL and 107 
encephalomyocarditis virus internal ribosomal site (EMCV-IRES)) reduced the 108 
efficiency of HCV RNA replication. To overcome this issue, we tried to improve the 109 
efficiency of HCV RNA replication by introducing adaptive mutations and by 110 
subcloning the parental cells.  111 
   Here, we developed JFH-1 HCV production reporter assay systems in HuH-7- and 112 
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Li23-derived cells using adaptive mutations and subcloned cells, which monitor the life 113 
cycle of HCV with luciferase activity. We also tested the effect of the mutations in 114 
NS5B from JFH-1 strain on RNA replication of the specific genotype 1b O strain. 115 
 116 
 117 
Results 118 
 119 
   HCV mutations caused by long-term cell culture.  The efficiency of HCV RNA 120 
replication depends on viral genetic mutations, host cells, and viral genome size. For 121 
development of the HCV reporter assay system, use of a longer viral genome reduced 122 
the efficiency of viral replication. To compensate for this issue, we tried to introduce 123 
adaptive mutations into the JFH-1 genome. We examined the viral sequences of JFH-1 124 
at 130 days after infection to HuH-7-derived RSc cells. We performed reverse 125 
transcription polymerase chain reaction (RT-PCR) for 3 parts of the viral genome, Core 126 
to NS2, NS3 to NS5A, and NS5B to 3’X. These 3 parts were separated by the AgeI, 127 
SpeI, BsrGI, and XbaI sites on the viral genome. We introduced PCR products into the 128 
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cloning vector and 3 independent clones were subjected to sequencing analysis. 129 
In the Core to NS2 region between the AgeI and SpeI sites (designated as AS), there 130 
were 8 common mutations with amino acid substitutions, Lysine to Glutamate at amino 131 
acid position 78 (K78E) in Core, P251L and A351D in E1, V402A, I414T, K715N in 132 
E2, Y771C in p7, and D962G in NS2 (Fig. 1a). In the NS3 to NS5A region between 133 
SpeI and BsrGI sites (designated as SB), there were 8 common mutations with amino 134 
acid substitutions, V1460I, M1611T in NS3, and I2270T, Q2307R, S2363L, M2392T, 135 
S2426A, and C2441S in NS5A (Fig.1b). In the NS5B to 3’X region between the BsrGI 136 
and XbaI sites (designated as BX), there was only 1 common mutation with an amino 137 
acid substitution, V2995L in NS5B (Fig. 1c). The determined sequences were examined 138 
for further study to enhance HCV RNA replication in the JFH-1 reporter assay. 139 
 140 
   The effect of genetic mutations on HCV RNA replication.  To monitor the viral 141 
life cycle more easily, we constructed dicistronic JFH-1 with a reporter gene, pJR/C-5B. 142 
The first cistron contained the RL gene and was translated by HCV IRES. The second 143 
cistron contained the JFH-1 open reading frame and was translated by EMCV IRES. 144 
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This construct facilitated monitoring of all steps of the viral life cycle by the 145 
quantification of RL activity. However, the use of a longer viral genome resulted in less 146 
replication efficiency. We tested the effect of amino acid substitution caused during 147 
long-term cell culture on HCV RNA replication. 148 
The amino acid substitution clusters from 3 independent clones in Core to NS2 (AS-1, 149 
AS-2, AS-3) were introduced into pJR/C-5B. The in vitro-transcribed HCV RNA was 150 
introduced into HuH-7-derived RSc cells, and the RL activities were monitored at 24, 151 
48, and 72 hours after electroporation (Fig. 2a). AS-3 exhibited higher replication 152 
efficiency than the wild type (WT). However, the replication efficiency of AS-2 was 153 
almost equal to that of the WT and AS-1 exhibited lower replication efficiency than the 154 
WT. AS-3 possessed the highest replication efficiency among the tested JFH-1 mutants; 155 
at 72 hours the luciferase value of this clone was approximately 100 times that at 24 156 
hours. 157 
The three pJR/C-5B constructs with mutations in NS3 to NS5A (SB-2, SB-3, and SB-4) 158 
were transcribed and introduced into RSc cells to compare the efficiency of HCV RNA 159 
replication (Fig. 2b). Unexpectedly, RL activity was not increased over the 72 hours 160 
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after electroporation and exhibited a pattern similar to JFH-1 without the GDD motif. 161 
This result indicates that the mutation in NS3 to NS5A exhibited negative efficiency on 162 
HCV RNA replication. 163 
Finally, we tested the effect of the mutations in the NS5B region on HCV RNA 164 
replication. BX-2 contains 2 mutations with amino acid substitution (H2505Q and 165 
V2995L) and BX-7 contains only V2995L (Fig. 2c). JFH-1 with mutation(s) of BX-2 or 166 
BX-7 exhibited strong enhancement of HCV RNA replication. These results indicate 167 
that V2995L works as a strong replication-enhancing mutation (REM) in JFH-1 HCV 168 
RNA replication. 169 
 170 
   The mutations in NS5B differently enhanced 1b and 2a HCV RNA replication.  171 
V2995L in NS5B is a common substitution in 3 clones and H2505Q is conserved in 2 172 
clones (BX-2 and BX-10). We examined the corresponding amino acids at positions 173 
2995 and 2505 in genotype 1b replication-competent HCV strains, O, 1B-4, and KAH5 174 
(Fig. 3a) (Nishimura et al., 2009). The histidine at amino acid position 2505 in 175 
JFH-1 is conserved in O, 1B-4, and KAH5 at the corresponding amino acid position 176 
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2482. The valine at amino acid position 2995 in JFH-1 is an alanine in O, 1B-4, and 177 
KAH5 at the corresponding amino acid position 2972 (Fig. 3a). It is not clear whether 178 
or not the adaptive mutation found in genotype 2a is effective in genotype 1b HCV. 179 
Therefore, we investigated the effect of V2995L and/or H2505Q substitution on 180 
genotype 1b HCV RNA replication. We introduced V2995L and/or H2505Q 181 
substitution into the subgenomic replicon, pOR/3-5B (HCV-O). In contrast to the case 182 
of JFH-1, H2505Q but not V2995L enhanced HCV-O RNA replication (Fig. 3b). These 183 
results indicate that the mutations in NS5B derived from JFH-1 functioned differently in 184 
genotype 1b HCV-O RNA replication.  185 
 186 
 187 
   HCV infection in the HuH-7- and Li23-derived cell lines.  The choice of host 188 
cells is important for the efficiency of HCV RNA replication as well as viral genetic 189 
mutations. The cured cells such as HuH-7.5, HuH-7.5.1, and our RSc cells exhibit 190 
higher replication efficiency than that of their parental HuH-7 cells (Ariumi et al., 191 
2007; Blight et al., 2002; Zhong et al., 2005). Therefore, we examined whether or 192 
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not subcloned Li23 cells may enhance HCV RNA replication. We performed serial 193 
subcloning of Li23 cells from Li23-derived ORL8c cells by the limiting dilution method 194 
(Fig. 4a). ORL8c cells are a cured cell line, in which genome-length HCV RNAs were 195 
eliminated by interferon (IFN) treatment (Kato et al., 2009). The subclonal 196 
Li23-derived cell lines were selected from among 50-100 independent single cells in 197 
96-well plates by 3-round limiting dilution from ORL8c cells (sFig. 1a). First, L8c15 198 
cells were selected from their parental ORL8c cells by limiting dilution. Then, C22 cells 199 
were selected from their parental L8c15 cells by limiting dilution. And finally, D7 cells 200 
were selected from C22 cells by limiting dilution (sFig.1b). Together, these steps 201 
resulted in the selection of 3 subclonal cell lines that respectively exhibited the strongest 202 
replication efficiency in each round selection. The lineages of the selected cell lines 203 
after 3 rounds of subcloning were L8c15, C22, and D7 cells, respectively.  204 
   We tested the subcloned cells for their HCV infectivities in comparison with HuH-7 205 
and HuH-7-derived RSc cells. We previously reported that RSc cells could highly 206 
support HCV replication and production (Kato et al., 2009). Li23 and its derived 207 
ORL8c, L8c15, C22, and D7 cells were infected using the supernatant from JR/C-5B 208 
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with BX-2 mutants replicating RSc cells at a moi of 0.2 (Fig. 4b and 4c). The RL 209 
activities were determined at 24, 48, 72, and 96 hours after infection and focus-forming 210 
units (FFUs)/ml were determined at 48 hours after infection. The efficiency of HCV 211 
infectivity was highest in D7 cells, followed in order by C22, L8c15, and Li23 cells. 212 
The HCV RNA replication in D7 cells was almost equal to that in RSc cells. These 213 
results suggest that the subcloned cell lines exhibit higher susceptibility to HCV 214 
infection than that of their parental cells. 215 
   Next, we further characterized the susceptibility of D7 cells to HCV infection in 216 
comparison with RSc cells, because D7 cells exhibited the highest susceptibility to 217 
HCV infection among the Li23-derived cell lines. D7 cells also exhibited the highest 218 
production and release of Core into the supernatant among the parental 219 
C22-derived subclonal cells (sFig. 1b). The susceptibility of the HCV reporter assay 220 
system to HCV infection was examined using HuH-7- and Li23-derived cells. 221 
Supernatants from JR/C-5B with AS-3 or with BX-2 mutations replicating RSc cells 222 
were used as inocula. The supernatant from authentic JFH-1 replicating RSc cells was 223 
used as a positive control. RSc and D7 cells were inoculated with each HCV containing 224 
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supernatant and the number of FFUs/ml was determined at 48 hours after infection. As 225 
shown in Fig. 4(d), the values of FFUs/ml for AS-3 were 2.5 x 104 and 1.0 x 104 in RSc 226 
and D7 cells, respectively. The values of FFUs/ml for BX-2 were 3.1 x 104 and 1.8 x 227 
104 in RSc and D7 cells, respectively. The values of FFUs/ml for authentic JFH-1 were 228 
2.9 x 105 and 1.2 x 105 in RSc and D7 cells, respectively. These results indicate that the 229 
infectivities of these 3 inocula were almost equal between RSc and D7 cells.  230 
   Next we examined Core expression after infection of HCV to RSc and D7 cells, as 231 
D7 cells exhibited the highest infectivity among the Li23-derived cell lines (Fig. 4e). 232 
Core was detected at 2, 3, and 4 days after infection of the supernatant from JR/C-5B 233 
with BX-2-infected RSc cells. Although the Core expression in D7 cells was slightly 234 
weaker than that in RSc cells, the signal of Core in HCV-infected D7 cells was equal to 235 
that in stable ORL8 cells. These results suggest that the JFH-1 reporter assay system in 236 
Li23 cells is useful not only for the RL assay but also for Core expression.  237 
 238 
   The expression of HCV receptors in parental and subclonal hepatoma cell lines. 239 
We further tested the expression of HCV receptors, CD81, scavenger receptor class B 240 
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member I (SR-BI), claudin-1 (CLDN1), and occludin (OCLN). We also examined the 241 
expression of the recently reported HCV entry factor, Niemann-Pick C1-like 1 242 
(NPC1L1) (Sainz et al. 2012). The expression levels of CD81 in Li23 and its subclonal 243 
cells were higher than that in HuH-7 and RSc cells (Fig. 5a). Although, the expression 244 
of CD81 in Li23-derived cell lines were lower than that in parental Li23 cells, 245 
interestingly the expression levels of CD81 increased, when the rounds of selection 246 
were going on. There is no tendency in the expression of SR-BI among the cell lines 247 
tested (Fig. 5b). The expressions of CLDN1 in Li23-derived cells were higher than that 248 
in parental Li23 cells (Fig. 5c). The expression levels of OCLN in Li23 and its 249 
subclonal cells were higher than those in HuH-7 and RSc cells (Fig. 5d). Finally, the 250 
expressions of NPC1L1 in Li23-derived cell lines were higher than that in parental Li23 251 
cells (Fig. 5e). It is noteworthy that the expression level of NPC1L1 in RSc cells was 252 
approximately 2 log (10) lower than that in parental HuH-7 cells. Taken these results 253 
together, the expressions of OCLN and NPC1L1 in Li23-derived cells were higher than 254 
that in parental Li23 cells. 255 
 256 
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   Life cycle of the HCV reporter assay system in Li23-derived cells.  We 257 
investigated whether or not D7 cells produce infectious HCV. First, D7 cells were 258 
inoculated using the supernatant from JR/C5B with BX-2 in RSc cells, and the 259 
supernatant was stocked at 17 days after infection. Then, the supernatant derived from 260 
the D7 cells was used as an inoculum for reinfection to naïve D7 cells. RL activities 261 
were determined at 2, 6, 10, and 14 days after reinfection (Fig. 6). The RL activity was 262 
increased after reinfection in D7 cells and reached a plateau at 10 days after reinfection. 263 
These data indicate that the JFH-1 reporter assay system is also useful for monitoring 264 
the HCV life cycle in Li23-derived cell lines.   265 
 266 
 267 
 268 
Discussion 269 
 270 
   In this study, we developed an HCV production reporter assay system using 2 271 
distinct hepatoma cell lines, HuH-7 and Li23. The robust HCV RNA replication and 272 
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viral production were achieved by the introduction of REMs into the structural 273 
region or into the NS5B region. These REMs were obtained from JFH-1-infected 274 
long-term cell culture. The two REMs in NS5B (H2505Q and V2995L substitutions) 275 
derived from JFH-1 had different effects on genotype 1b HCV-O RNA replication, and 276 
2a JFH-1 RNA replication. Furthermore, the subcloned Li23-derived D7 cells produced 277 
by serial limiting dilution supported this HCV production reporter assay system.  278 
   Several groups have reported JFH-I reporter virus systems (Koutsoudakis et al., 279 
2006; Marcello et al., 2006; Pietschmann et al., 2002; Wakita et al., 2005). 280 
However, robust reporter virus production was limited within the study using 281 
HuH-7-derived cells. Therefore, we attempted to developed a JFH-1 reporter virus assay 282 
system using our previously reported line of Li23 cells (Kato et al., 2009).  283 
   The introduction of RL and EMCV-IRES genes into the HCV gene lengthened the 284 
genome size of HCV by approximately 1.9 kb and led to a reduction in the efficiency of 285 
HCV RNA replication. To overcome this disadvantage, we adopted the following 286 
strategies: (1) Introduce the REMs; (2) Select the cloned Li23-derived cells with a 287 
highly permissive host condition by the serial limiting dilution method. For the first 288 
 19 
purpose, we performed sequence analyses for HCV RNA from JFH-1-infected RSc 289 
cells. The mutations from Core to the NS2 or NS5B region enhanced HCV RNA 290 
replication. However, the combination of these mutations from two different regions 291 
reduced HCV RNA replication (sFigs. 2a-c). The reason for this result may be that these 292 
2 mutation clusters were obtained from distinct RT-PCR amplified clones and they were 293 
not necessarily located on the same viral genome. It had been reported that the 294 
combination of REMs exhibited an antagonistic effect on HCV RNA replication 295 
(Lohmann et al., 2001). For the second purpose, we selected the highly permissive 296 
Li23-derived clonal cells by the limiting dilution method. We obtained 3 Li23-derived 297 
subclonal cell lines, L8c15, C22, and D7, in order from parental Li23-derived ORL8c 298 
cells. The efficiency of infectivity was highest in D7 cells, followed in order by C22, 299 
L8c15, and Li23 cells. D7 cells were highly permissive for infection of HCV with 300 
NS5B mutations. 301 
   As shown in Fig. 3(a), the histidine at amino acid position 2505 in JFH-1 was 302 
conserved in the replication competent O, 1B-4, and KAH5 strains at the corresponding 303 
amino acid position 2482. The valine at amino acid position 2995 in JFH-1 was alanine 304 
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in O, 1B-4, and KAH5 strains at the corresponding amino acid position 2972. The 305 
REMs in genotype 1b HCV were usually obtained by the selection with neomycin after 306 
HCV RNA electroporation. Pietschmann et al. reported that the REM impaired the 307 
infectious viral production (Pietschmann et al., 2009). Most of the REMs were 308 
located in the NS3 and NS5A regions (Abe et al., 2007; Blight et al., 2002; 309 
Lohmann et al., 2001; Pietschmann et al., 2002). NS5A is a key molecule for 310 
viral production and REMs affect the phosphorylation status of NS5A and the 311 
interaction with Core (Kato et al., 2008; Masaki et al., 2008; Tellinghuisen et al., 312 
2008). In contrast, our REMs in NS5B were obtained in JFH-1-infected long-term cell 313 
culture without drug selection. Taking this information into account, we considered that 314 
H2505Q in NS5B might not interfere with the genotype 1b viral production. We 315 
attempted to apply this REM from genotype 2a to genotype 1b and found that H2505Q 316 
enhanced replication of the genotype 1b HCV-O replicon. We are currently 317 
investigating whether or not our NS5B REM could enhance genotype 1b HCV 318 
production. As for the amino acid substitution at 2995 in JFH-1 (2972 in genotype 1b), 319 
we should be careful in interpretation, because the backgrounds at this position are 320 
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different between genotypes 2 and 1. HCV database (http://s2as02.genes.nig.ac.jp/) 321 
analysis revealed that the consensus amino acid at 2995 in genotype 2 and at 2972 in 322 
genotype 1 was valine and alanine, respectively. Furthermore, alanine and valine are not 323 
found at 2995 in genotype 2 and at 2972 in genotype 1, respectively. These observations 324 
indicate that amino acid substitution between alanine and valine at these positions may 325 
be lethal for both genotype HCVs. Amino acid at 2995 in genotype 2 (2972 in genotype 326 
1) is just upstream of cis-acting replication element in NS5B. Therefore, RNA at this 327 
position may affect the HCV RNA replication. To clarify this issue, further study will 328 
be needed.   329 
   A comparative study using HuH-7- and Li23-based JFH-1 reporter assay systems 330 
would be expected to reveal new information on the viral entry and release steps, 331 
because the backgrounds of these cells are different. Our recent study on these cells 332 
revealed the difference in sensitivities to anti-HCV reagents, including ribavirin and 333 
methotrexate (Mori et al., 2011; Ueda et al., 2011). Furthermore, the IL28B genotype 334 
was different between HuH-7 and Li23 cells. The IL28B genotype (rs8099917) of 335 
HuH-7 cells were resistant to pegylated IFN and ribavirin and that of Li23 cells was 336 
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sensitive to pegylated IFN and ribavirin (Ikeda et al. unpublished data).  337 
   Recently, it was reported that stable expression of miR122 enhanced JFH-1 HCV 338 
production in Hep3B and HepG2 (Kambara et al., 2011; Narbus et al., 2011). It is 339 
noteworthy that the expression of miR122 in Li23-derived cells was almost the same as 340 
that in HuH-7 cells (sFig. 3). The high level expression of miR122 in Li23 cells may be 341 
one of the reasons that Li23 cells can support HCV production as robust as that in 342 
HuH-7 cells among the hepatocyte-derived cell lines. Interestingly, the expression 343 
levels of miR122 are higher in ORL8c, L8c15, and D7 cells, but not in C22 cells than 344 
that in parental Li23 cells (sFig. 3). This result suggests that the expression level of 345 
miR122 may partly contribute to the fitness of HCV replication and production. 346 
    So far, we have only little information regarding the mechanism that subclonal 347 
cells support HCV replication and production more efficiently than the parental cells. In 348 
this study, we found that the expression levels of CLDN1 and NPC1L1 in Li23-derived 349 
subclonal cells were higher than those in the parental Li23 cells. These results suggest 350 
that high expression level of these entry factors in the Li23-derived subclonal cells may 351 
contribute to enhance the viral entry. In the course of the experiment to determine the 352 
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expression levels of NPC1L1 in HuH-7- and Li23-derived cell lines, we found that RSc 353 
cells expressed very low level of NPC1L1 compared with the parental HuH-7 cells. The 354 
possible mechanisms for this are (1) very low expression of NPC1L1 is enough for 355 
HCV entry, (2) unknown entry factor compensate for NPC1L1 in the entry step in RSc 356 
cells. Further study will be needed to clarify this issue.  357 
    In summary, we have developed JHF-1 reporter assay systems using 358 
HuH-7-derived RSc and Li23-derived D7 cells. The expression levels of CLDN1 and 359 
NP1C1L were higher than those in the parental Li23 cells. We found different effects of 360 
REMs (V2995L and H2505Q substitutions) in NS5B on genotypes 2a and 1b HCV 361 
strains in viral RNA replication. These findings will become useful tools in the study of 362 
the life cycle of HCV. 363 
 364 
 365 
Materials and Methods 366 
 367 
   Cell cultures.  RSc cells and ORL8c cells were derived from the cell lines HuH-7 368 
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and Li23 as previously described (Kato et al., 2009). L8c15 cells were selected from 369 
ORL8c cells by limiting dilution. C22 cells were selected from the L8c15 cell line by 370 
limiting dilution. D7 cells were selected from C22 cells by limiting dilution. HuH-7 and 371 
RSc cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 372 
10% fetal bovine serum (FBS). Li23-derived cell lines were maintained in F12 medium 373 
and DMEM (1:1 in volume) supplemented with 1% FBS and epidermal growth factor 374 
(50 ng/ml) as described previously (Kato et al., 2009).  375 
 376 
   RT-PCR and sequencing analysis.  RSc cells were infected with cell 377 
culture-grown HCV (HCVcc) and cultured for 130 days. Total RNAs from these cells 378 
were prepared using an RNeasy extraction kit (Qiagen, GmbH, Germany). These 379 
RNA samples were used for RT-PCR in order to amplify the Core to NS2 region (4.0 380 
kb), NS3 to NS5A region (3.6 kb), and NS5B to 3’X region (1.9 kb). RT was performed 381 
with the Oligo dA23 primer, 5’-AAAAAAAAAAAAAAAAAAAAAAA-3’. The 382 
following primer pair was employed to amplify the Core to NS2 region: for JFH-1/AgeI, 383 
5’-CCCAAGCTTACCGGTGAGTACACCGGAATTGC-3’; and for JFH-1/SpeIR, 384 
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5’-TGCCATGTGCCTTGGATAGGTACG -3’. The primer pair JFH-1/SpeI: 385 
5’-CCCAGGGGTACAAAGTACTAGTGC-3’ and JFH-1/BsrGIR: 386 
5’-CCCAAGCTTTACCTTTTTAGCCCTCTGTGAGGC-3’ was employed to amplify 387 
NS3 to NS5A region. The primer pair JFH-1/BsrGI: 388 
5’-CCGCTCGAGACCCTTTGAGTAACTCGCTGTTGC-3’ and JFH-1/XbaIR: 389 
5’-GCTCTAGACATGATCTGCAGAGAGACCAGTTAC-3’ was employed to amplify 390 
NS5B to 3’X region. SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA) 391 
and KOD-plus DNA polymerase (Toyobo, Osaka, Japan) were used for RT and PCR, 392 
respectively. PCR products were ligated into pBluescript II and 3 independent clones 393 
were subjected to sequencing analysis.  394 
 395 
   Plasmid construction.  pJR/C-5B plasmid is a dicistronic HCV JFH-1 construct. 396 
The RL genes and HCV open reading frame were introduced in the first cistron and in 397 
the second cistron, respectively. To construct this plasmid, we fused the JFH-1 5’ 398 
5’untranslated region (UTR) region with the RL gene by overlap PCR, and the PCR 399 
products were ligated into pFGR-JFH-1 (GenBank Accession No. AB237837) at the 400 
 26 
AgeI and PmeI sites. For the first PCR, the primer pair 401 
5’-GCGCCTAGCCATGGCGTTAGTATG -3’ (for J5dC) and  402 
5’-AAGCCATGGCCGGCCCTGGGCGACGGTTGGTGTTTCTTTTGG-3’ (for 403 
J5dCR) was employed to amplify the 5’UTR, and the primer pair 404 
5’-AACCGTCGCCCAGGGCCGGCCATGGCTTCCAAGGTGTACGACCCC-3’ (for 405 
JRL) and 5’-TCGAAATCTCGTGATGGCAGGTTGG-3’ (for JRLR) was employed to 406 
amplify the RL region. These first PCR products were used in the second PCR as the 407 
templates. For the second PCR, the primer pair J5dC and JRLR was employed to 408 
amplify 5’UTR and RL. KOD-plus DNA polymerase was used for PCR. 409 
The H2505H and/or A2995 mutations were introduced into the HCV-O replicon by 410 
QuickChange mutagenesis (Stratagene, La Jolla, CA) as described previously (Ikeda et 411 
al., 2002). 412 
 413 
   Luciferase reporter assay.  For the luciferase assay, 1.0~1.5 ! 104 414 
HCV-harboring cells were plated onto 24-well plates in triplicate and were cultured for 415 
24 to 96 hours after electroporation or infection, as described previously (Ikeda et al., 416 
 27 
2005). The cells were harvested with renilla lysis reagent (Promega, Madison, WI) and 417 
subjected to RL assay according to the manufacturer’s protocol. 418 
 419 
   Western blot analysis.  The preparation of cell lysates, sodium dodecyl 420 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotting were 421 
performed as described previously (Kato et al., 2003). The antibodies used in this study 422 
were Core- (CP11; Institute of Immunology, Tokyo, Japan) and "-actin antibody 423 
(AC-15; Sigma, St. Louis, MO). Immunocomplexes were detected with a Renaissance 424 
enhanced chemiluminescence assay (Perkin Elmer Life Science, Boston, MA). 425 
 426 
   HCV infection and determination of FFU.  To determine FFU/ml, 6 x 103 cells 427 
were plated onto a 96-well plate 24 hours before infection. The supernatant of HCV 428 
RNA-replicating cells was serially diluted and was used as an inoculum. Forty-eight 429 
hours after infection, the cells were fixed and Core was stained with anti-Core antibody 430 
and HRP-conjugated mouse anti-IgG antibody. Then, the expression of Core was 431 
visualized with a DAB substrate kit (DAKO). The culture supernatants and cells were 432 
 28 
collected for quantification of the Core by enzyme-linked immunosorbent assay 433 
(ELISA) (Mitsubishi Kagaku Bio-Clinical Laboratories, Tokyo, Japan). 434 
 435 
   The quantitative RT-PCR analysis. The quantitative RT-PCR analysis for HCV 436 
receptors was performed using real-time LightCycle PCR (Roche Diagnostics, Basel, 437 
Switzerland) as described previously (Ikeda et al., 2005). The primer pairs for CD81, 438 
SR-BI, CLDN1, and OCLN were previously reported by Nakamuta et al. (Nakamuta et 439 
al., 2011). The primer pair, NPC1L1: 5’-agatcttcttcttccgcctcca-3’ and NPC1L1R: 440 
5’-tgccagagccgggttaac-3’ was used for NPC1L1. 441 
 442 
   Statistical analysis. The luciferase activities were statistically compared between 443 
the various treatment groups using Student’s t-test. P values of less than 0.05 were 444 
considered statistically significant. The mean ± standard deviation is determined from at 445 
least three independent experiments. 446 
 447 
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 573 
Figure Legends 574 
 575 
Fig. 1. The genetic mutations with amino acid substitutions during long-term HCV 576 
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infection. RT-PCR was performed for HCV RNAs from HuH-7 cells at 130 days after 577 
JFH-1 infection. PCR products were subcloned into pBluescript II plasmid. (a) Three 578 
clones of the Core to NS2 region between the AgeI and SpeI sites (AS) were subjected 579 
to sequencing analysis. (b) Three clones of the NS3 to NS5A region between the SpeI 580 
and BsrGI sites (SB) were subjected to sequencing analysis. (c) Three clones of the 581 
NS5B to 3’X region between the BsrGI and XbaI sites (BX) were subjected to 582 
sequencing analysis. Closed and open triangles are conservative and nonconservative 583 
amino acid substitutions, respectively. 584 
 585 
Fig. 2. The effect of amino acid substitutions on HCV RNA replication. (a) The Core to 586 
NS2 region. (b) The NS3 to NS5A region. (c) NS5B to 3’X region. Amino acid 587 
substitutions were introduced into pJR/C5B and in vitro-synthesized RNAs were 588 
electroporated into HuH-7-derived RSc cells. RL activity was determined at 24, 48, and 589 
72 hours after electroporation. dGDD is a negative control without the GDD motif and 590 
WT is a wild type. 591 
 592 
 38 
Fig. 3. The effect of amino acid substitutions in NS5B on genotype 1b and 2a HCV 593 
RNA replication. (a) Alignment of amino acids at positions 2505 (JFH-1) and 2482 594 
(genotype 1b) and around the adjacent region (upper panel). Alignment of amino acid at 595 
positions 2995 (JFH-1) and 2972 (genotype 1b) and around the adjacent region (lower 596 
panel). The HCV strains of O, KAH5, and 1B-4 belong to genotype 1b. (b) H2505Q 597 
and/or V2995L were introduced into the HCV-O subgenomic replicon (pOR/3-5B), and 598 
transcribed RNAs were electroporated into RSc cells. The RL activities were tested at 599 
24, 48, and 72 hours after infection. dGDD is a negative control without a GDD motif 600 
and WT is a wild type. 601 
 602 
Fig. 4. HCV infection in HuH-7- and Li23-derived cell lines. (a) History of the selection 603 
of subclonal Li23-derived cell lines. (b) HuH-7, HuH-7–derived RSc, Li23-derived 604 
ORL8c, L8c15, C22, and D7 cells were inoculated with supernatant from JR/C5B/BX-2 605 
replicating RSc cells. (c) FFUs were determined at 48 hour after infection of HCV to 606 
HuH-7- and Li23-derived cells using the supernatant from JR/C5B/BX-2 replicating 607 
RSc cells. (d) FFUs were determined at 48 hours after infection of HCV to RSc or D7 608 
 39 
cells using the supernatant from JR/C5B/AS-3- or JR/C5B/BX-2-replicating RSc cells. 609 
The supernatant from authentic JFH-1-replicating RSc cells was used as a positive 610 
control. (e) The Core expressions in RSc or D7 cells were determined at 1, 2, 3, and 4 611 
days after infection of JFH-1 with BX-2 mutations. Lanes 1 and 6 are mock-infected 612 
cells. Lanes 2 and 7 are cells at 1 day after infection. Lanes 3 and 8 are cells at 2 days 613 
after infection. Lanes 4 and 9 are cells at 3 days after infection. Lanes 5 and 10 are cells 614 
at 4 days after infection. Lanes 11 and 12 are OR6c and OR6 cells, respectively. Lanes 615 
13 and 14 are ORL8c and ORL8 cells, respectively. OR6 and ORL8 were used as 616 
positive controls. OR6c and OR8c were used as negative controls. 617 
 618 
Fig. 5. The expression levels of HCV receptors in HuH-7- and Li23-derived cells. 619 
Quantitative RT-PCR was performed for CD81, SR-B1, CLDN1, OCLN, and NPC1L1 620 
as described in Materials and Methods. Relative expression levels of mRNA were 621 
shown, when the expression level of each receptor in HuH-7 was assigned to be 1. 622 
GAPDH was used as an internal control. Experiments were done in triplicate. 623 
 624 
 40 
Fig. 6. HCV life cycle in Li23-derived D7 cells. D7 cells were inoculated with the 625 
supernatant from D7 cells after infection of JFH-1 with BX-2 mutants. RL activities 626 
were tested at 2, 6, 10, and 14 days after infection. 627 
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Supplementary Figure Legends 1 
 2 
sFig. 1. Selection of subclonal cell lines derived from Li23 cells.  3 
(a) Selection of subclonal cell lines from ORL8c by 3 round limiting dilutions. (b) 4 
Selection of D7 cells from parental C22 cells. Nine clonal cell lines derived from 5 
Li23-derived C22 cells were examined for their replication efficiency and Core 6 
production by RL activity and ELISA. 7 
 8 
sFig. 2. The effect of amino acid substitutions on HCV RNA replication. (a) The 9 
mutations in the Core to NS2 region (AS-3) were tested for their replication efficiency 10 
in combination with those of the NS3 to NS5A region (SB-2, SB-3, and SB-4). RL 11 
activity was determined at 24, 48, and 72 hours. (b) The mutations in the NS5B to 3’X 12 
region (BX-2) were tested for their replication efficiency in combination with those of 13 
the NS3 to NS5A region (SB-2, SB-3, and SB-4). RL activity was determined at 24, 48, 14 
and 72 hours. (c) The mutations in the Core to NS2 region (AS-3) were tested for their 15 
replication efficiency in combination with that of the NS5B to 3’X region (BX-2). RL 16 
 2 
activity was determined at 24, 48, and 72 hours. dGDD is a negative control without the 17 
GDD motif and WT is a wild type. 18 
 19 
sFig. 3. Mir122 expression in HuH-7- and Li23-derived cell lines. RNA preparations  20 
for HuH-7, RSc, Li23, ORL8c, L8c15, C22, and D7 cells were performed with 21 
ISOGEN (Nippon Gene, Tokyo, Japan). The extracted RNAs were subjected to 22 
quantitative RT-PCR for miR122 using Mir-XTM miRNA qRT-PCR SYBR® Kit 23 
(Takara Bio, Shiga, Japan) according to the manufacture’s instruction. U6 was used as 24 
an internal control. 25 
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